FDA approves Kerendia for chronic kidney disease associated with type 1 diabetes
The FDA has expanded the approved use of Kerendia to adults with chronic kidney disease associated with type 1 diabetes, introducing a new treatment option for this high-risk population.
Kerendia, or finerenone, is a non-steroidal mineralocorticoid receptor antagonist already used in chronic kidney disease associated with type 2 diabetes and can now also be prescribed for eligible adults with type 1 diabetes.
The expanded indication addresses an area with limited therapeutic innovation and gives clinicians another option for reducing kidney and cardiovascular risks associated with diabetic kidney disease.
Field | Content |
Alert Type | Approval |
Drug Name | Finerenone |
Brand Name | Kerendia |
Company | Bayer |
Regulatory Authority | U.S. Food and Drug Administration |
Approval Type | Indication expansion |
Indication | Chronic kidney disease associated with type 1 diabetes in adults |
Therapy Area(s) | Nephrology; diabetes; cardiometabolic disease |
Technology or Modality | Non-steroidal mineralocorticoid receptor antagonist |
Geography | United States |
What Happened | The FDA approved Kerendia for adults with chronic kidney disease associated with type 1 diabetes. |
Why It Matters | The approval creates a new treatment option for a population with substantial kidney and cardiovascular risk and historically limited disease-specific pharmacological choices. |
Supporting Context | Finerenone is already approved for chronic kidney disease associated with type 2 diabetes and acts by selectively blocking mineralocorticoid receptor overactivation. |
Key Takeaway | Kerendia's FDA label now includes adults with chronic kidney disease associated with type 1 diabetes. |
What to Watch | Clinical adoption, incorporation into kidney-disease treatment pathways and real-world outcomes in people with type 1 diabetes. |
Primary Source | Bayer |
Relevant Date | 17 September 2026 |
Discover how nuaxia can support your next medical education initiative:
Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector
Contact us on: support@nuaxia.com
Commentaires